Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The point of a Yahoo poster is close to mine:
http://finance.yahoo.com/quote/ARIA/community?p=ARIA
There are some very good posts on Yahoo.
Shares Outstanding: 194.20M. Do the buyers think the buyout deal will be backed out and SP will dropped to $12?
Volume history since 01/09/2017;
01/18/2017 11,934,980
01/17/2017 13,180,430
01/13/2017 14,657,840
01/12/2017 14,661,930
01/11/2017 35,796,600
01/10/2017 62,151,550
01/09/2017 142,489,800
Thanks, Jess. Who has been being the buyer of ARIA shares since Jan. 7, 21017 do you think? I agree with you and I am still holding my 100k+ ARIA shares. BR? LOL! He claimed he sold at $23.75. Did he really have any shares to sell? Wasn't he talked into selling at $3- by iAndy early Nov., 2013? How's the class action lawsuit he joined against Ariad going? Did BR get $0.001 per 1000 shares he sold at $3-? He did tell the truth that he became an ARIA short on the Yahoo board after the 2013-10-09 flash crash.
Hello!
Dr. Cortes talked about new clinical trials with 30mg Pona + Aspirin/Statin on Dec. 12. 2013.
Video:
Tapered dose steroids were used to resolve symptoms over 1 week, and patients restarted the drug at 90 mg/d without further pulmonary symptoms, he said. Future studies will employ a step-up approach, initiating the drug at 90 mg/d for 7 days before moving up to 180 mg/d.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94559928
Who's the institutional short seller Adam Feuerstein spoke with Monday morning?
In fact, the slide in Adam Feuerstein's article titled "Ariad Pharma Short Seller Explains Why Takeover Rumor Is Bunk" was published already on Nov. 22, 2013:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94360661
I like the slide very much. It was actually referred as "Novartis' Ariad Killer" slide.
-----------
I had a post talking about the "Novartis' Ariad Killer" on Nov.23, 2013:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94364963
Your stop losses help the finely tuned trading programs that are installed on the hedge funds' trading machines.
"The best is yet to come," said Ariad CEO Harvey Berger.
Don't lose your ARIA shares. With Alex Denner in activist action, the buyout may be true.
Even not, Ariad will become ... ...
"Alex Denner will help make an Ariad turnaround story. When a company is broken, he knows what should be done to fix it," ariad_investor posted on Oct. 29, 2013. "Alex Denner is ranked No. 1 among the 25 most influential people in biopharma today. Now, he has bought 11.5m ARIA shares. He will get onto Ariad's board of directors and guide Ariad's turnaround, I think.
mikies_back: "Your a smart guy and way ahead of the curve my man!".
ariad_investor: "I learned it from grandma_of_jbraika."
"People learn from each other."
MM's may induce an even more severe short squeeze! Watch the fun!
It is not a matter of whether a Big Pharmy wants to buy this company or NOT. It is a matter of whether the company wants to sell itself to a Big Pharmy or NOT.
When ARIA was at $1.70 in 2009, Dr. Harvey Berger said it would be at least $65/share for an acceptable buyout offer
Tysabri's withdrawal from market made BIIB drop to $30. Now BIIB is almost a $300 stock.
sing229: "I bought BIIB at $38 when Tysabri was banned."
trading_cyclist: "you lucky (clever) @*#%@#^]. Serious, congrats and hoping that ARIA does the same thing."
What will happen to ARIA's price now that the ban on Iclusig has been lifted?
Tysabri's withdrawal from market made BIIB drop to $30. After the ban on Tysabri was lifted, BIIB started to fly. BIIB is almost a $300 now.
400.00 OR MORE a shares after couples FORWARD splits like IDPH BEFORE IT BOUGHT BIOGEN & then became BIOGEN IDEC (BIIB). I only invest in 2 Biotech IDPH and ARIA. I sold IDPH too early but not ARIA.
No man ever steps in the same river twice, for it's not the same river and he's not the same man.
"$400 after 2-3 splits adjusted. ARIA is 10 times better than BIIB." - posted by ninhp32809, Jul 29, 2009 9:39 AM
"I will not sell until ARIA get to the promise land ( 400.00 after 2-3 splits adjusted) like BIIB ( former IDPH ).
ARIA is ten times better than IDPH ."
Ninhp32809 predicted ARIA would be the next BIIB.
Ninhp32809's prophecies has come true! Now, ARIA has to undergo what BIIB has undergone.
God bless Ariad longs! Just relax and enjoy the online entertainment. ARIA will recover and create new highs.
Tysabri's withdrawal from market made BIIB drop to $30. Now BIIB is almost a $300 stock.
sing229: "I bought BIIB at $38 when Tysabri was banned."
trading_cyclist: "you lucky (clever) @*#%@#^]. Serious, congrats and hoping that ARIA does the same thing."
Role of anti-coagulants and anti-platelet drugs - Interventions
Benefit-risk at lower doses -Randomized trial of multiple dose levels to begin 2H 2014
--- From Slide 17 of of Ariad CEO's 2014-01-14 JP Morgan Conference Presentation
"It really depends on the dose and the data we collect in the front line. Clearly, we need to run trials at lower doses. We don't rule out the front line. But it would have to be based upon data, not just hypothesis."
4. The poison pill provision on Nov. 1 was the most positive indication. It indicates that the next BIIB/AMGN is not for sale in addition to thwarting off hostile takeovers. It indicates that Ariad CEO is not knocked down by the unexpected setback or conspired takedown. The company remains confident on itself. It was the CEO's ego or his confidence on Ariad that help ariadinvestor and me decide to invest in the stock of this company 14 years ago.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=95668935
FMR most certainly lightened their load substantially in 4th quarter? Dead wrong!
1. The 27,392,509 shares filed on 11/08/2013 is NOT FMR's holdings at the end of the 3rd quarter. On 09/30/2013, FMR was holding 19,590,830 shares as every body can verify now.
2 Nov. 8 is after the blowup in early October, rather than before it.
3. FMR filed its 13G on Nov. 8, 8 days after the end of the 3rd quarter, NOT 45 days after.
4. FMR filed 13G again on 01/10/2014 (rather than February 15th), 10 days after 12/31/2013, NOT 45 days after the end of the 4th quarter.
5. My statements about Fidelity's ARIA holdings are precisely accurate and meaningful. It means FMR continued buying and holding ARIA shares after the conspired takedown, indicating the largest mutual fund family remain confident on Ariad Pharmaceuticals. Fidelity knows what it owns.
6. Fidelity still holds its core positions of 17 million shares. Fidelity's core holdings have been 17 million shares for years. Its trading shares are basically 2+ million shares.
7. FMR's 4Q end holdings should be more than 17 millions. The 17 million shares reported in the latest 13G should be what FMR held as of Jan. 10, 2014.
8. The statement saying "Fidelity most certainly lightened their load substantially" is dead wrong!
I believe that FMR added 10 million shares mostly at floor prices after the crash, and took profits from selling its long-term-held 10 million shares bough years ago. As the result, Fidelity's core holding of ARIA remains the same, which shows they still buy and hold the gold bags of ARIA shares.
It is understandable that FMR, on the Iclusig-return-to-market news, sold 10 million shares that they bought in 1Q 2010 at $2.45-$3.44. The gains will be long term capital gains (15% tax rate, good for Fidelity mutual funds holders). Fidelity bought 15 million shares in 1Q 2010.
Advised by Peter Lynch, Fidelity Fund Managers own what they know. "Own what you know," says Peter Lynch. FMR knows ARIA.
It's precisely true that FMR increased ARIA holdings to 27,392,509.
Details (Link): Truth about Fidelity's 13G filing and ARIA holdings.
Hint: “No man ever steps in the same river twice, for it's not the same river and he's not the same man.”
It was posted by spring_is_coming_soon in Nov., 2013. It is precisely true as every body can verify by checking Fidelity's 13G filing dated November 8, 2013:
Item 1: Reporting Person - Edward C. Johnson 3d
Item 9: 27,392,509
Item 11: 14.798%
FMR increased ARIA holdings to 27,392,509 shares from 17,289,316 shares. 13G filling date: November 8, 2013.
services.corporate-ir.net/SEC.Enhanced/SecCapsule.aspx?c=118422&fid=9096378
I am not sure whether it was Fidelity's end of 3rd quarter filing or Fidelity added 10 million shares after the flash crash. If it is the former, then fidelity is the largest loser on Ariad. However, Fidelity plays with money using other people's money. If it is the latter, it seems to be good news for ARIA shareholders.
Early 2000, Fidelity was the No. 1 institutional holder with 1 million shares. Fidelity sold all of 1 million shares after ARIA started to drop from $48.50 early March, 2000. Fidelity had been keeping on the sideline until the 1st quarter of 2010 when it bought 15 million ARIA shares. Fidelity has been the No. 1 institutional holder of ARA since then.
FMR added 10 million shares mostly after the 10/09/2013 crash, possibly after/on 10/31/2013 at $2+.
It is understandable that FMR, on the Iclusig-return-to-market news, sold 10 million shares that they bought in 1Q 2010 at $2.45-$3.44. The gains will be long term capital gains (15% tax rate, good for Fidelity mutual funds holders). Fidelity bought 15 million shares in 1Q 2013.
FMR's held 17 million shares at the end of 2Q 2013. As of 11/08/2013 when it filled the previous 13G, FMR added 10 million shares, totally holding 27 million shares.
Fidelity's core holdings have been 17 million shares for years. Its trading shares are basically 2+ million shares.
Fidelity's 13G filing - Fidelity increased ARIA holdings to 27,392,509 shares from 17,289,316 shares, filling date: November 8. Fidelity has been the No. 1 institutional holder of ARA since the 1st quarter of 2010 when it bought 15 million ARIA shares.
FMR knows what it owns. The largest mutual fund company continued to buy and hold ARIA shares after the plotted flash crash. Fidelity has been the No. 1 institutional holder of ARIA since the 1st quarter of 2010.
I thought FMR would sell all of its ARIA holdings on the Oct. 9 bad news as it did in 1999 because of Ariad's big financial problem. It has turned out that Fidelity kept buying and holding this stock.
http://services.corporate-ir.net/SEC.Enhanced/SecCapsule.aspx?c=118422&fid=9096378
Fidelity is confident on Ariad, isn't it?
Ponatinib is effective as initial therapy for CML-CP resulting in high rates of cytogenetic and molecular responses at early timepoints. Therapy with ponatinib is well tolerated with transient elevated lipase being the most common toxicity. In view of the frequency of dose reductions and considering the excellent responses achieved, the trial has been modified to explore 30 mg as initial dose.
"Ninhp32809 predicts ARIA will be the next BIIB. Like Tysabri, the hold on Iclusig will removed by FDA." - posted by ariadinvestor on 10/14/2013.
"Ninhp32809's Prophecies come true! Now, ARIA has to undergo what BIIB has undergone.
God bless Ariad longs! Just relax and enjoy the online entertainment. ARIA will recover."
Tysabri's withdrawal from market made BIIB drop to $30. Now BIIB is almost a $300 stock.
sing229: "I bought BIIB at $38 when Tysabri was banned."
trading_cyclist: "you lucky (clever) @*#%@#^]. Serious, congrats and hoping that ARIA does the same thing."
"Ninhp32809 predicts ARIA will be the next BIIB. Like Tysabri, the hold on Iclusig will removed by FDA." - posted by ariadinvestor on 10/14/2013.
"Ninhp32809's Prophecies come true! Now, ARIA has to undergo what BIIB has undergone.
God bless Ariad longs! Just relax. ARIA will recover."
Tysabri's withdrawal from market made BIIB drop to $30. Now BIIB is almost a $300 stock.
sing229: "I bought BIIB at $38 when Tysabri was banned."
trading_cyclist: "you lucky (clever) @*#%@#^]. Serious, congrats and hoping that ARIA does the same thing."
"Ninhp32809 predicts ARIA will be the next BIIB. Like Tysabri, the hold on Iclusig will removed by FDA." - posted by ariadinvestor on 10/14/2013.
"Ninhp32809's Prophecies come true! Now, ARIA has to undergo what BIIB has undergone.
God bless Ariad longs! Just relax and enjoy the online entertainment of taunting the bashers and the frauds$fakes. ARIA will recover."
TYSABRI® Multiple Sclerosis Clinical Trial Hold Lifted by FDA; Biogen Idec and Elan to Resume Clinical Trial Dosing in MS, 15 February 2006,
CAMBRIDGE, Mass. and DUBLIN, Ireland--(BUSINESS WIRE)--Feb. 15, 2006--Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc. (NYSE: ELN) announced today that the Food and Drug Administration (FDA) informed the companies that they have removed the hold on clinical trial dosing of TYSABRI® (natalizumab) in multiple sclerosis (MS) in the U.S. The companies expect to begin an open label, multi-center safety extension study of TYSABRI monotherapy in the U.S. and internationally in the coming weeks. Patients who previously participated in the Phase III MS program are eligible for entry.
Tysabri's withdrawal from market made BIIB drop to $30. Now BIIB is almost a $300 stock.
sing229: "I bought BIIB at $38 when Tysabri was banned."
trading_cyclist: "you lucky (clever) @*#%@#^]. Serious, congrats and hoping that ARIA does the same thing."
This is the time to be short / Puts.
The CEO's goal is to build Ariad into the next Amgen according to my stepdaughter who used to be an Ariad employee.
I like Harvey Berger's goal and trust the Ariad CEO.
While BofA's RachelMcMinn is not sure Ariad can survive, I believe ARIA will become the next BIIB or AMGN.
Shorts and longs have quite a different perspective on the Ariad
Side Effects of Water - Right things must be consumed in right amount: Iclusig remains highly effective with few side effects at low doses per cancer patients.
As we always know too much of anything is not good, can you think of one thing that even if consumed a lot doesn't have any side effects? Oh many of you must be thinking of Water right? Then there you are caught! But before telling you why it's not water, I will remind you that right things must be consumed in right amount.
Water side effects is a very gradual process and the three major water side effects you may suffer (with of course conditions applied) are:
1. Weight Gain
2. Stressed Kidneys - This side effect could be fatal for those who have kidney problems
3. Poor Digestion
"The low dose therapy is highly effective with very minimal side effects. I have been on this treatment for two years and 4 months. Originally started at 45mg and after 1 month had adverse side effects (pancreatitus), the dosage was cut to 15 mg. Within 1 month the leukemia was undetectable and has stayed that way. This is a far better response than I had on any of the other TKI's either in development or FDA approved. Not only did every other TKI lose effacacy, the side effects on some of them were far worse than Iclusig. Admittedly this is anechdotal and specific only to my case but it does show that there is much more to be learned about this drug and the potential for market success. The other more disconcerting issue to me personally is that if this drug is no longer available, I have no other treatment options. I do not have the T351I mutation so that has no bearing on the effacy of the drug. I realize that this is all looked at from a business perspective - at least I, and many others like me, demonstrate that there is a potential market for this drug."
1 in 4 were getting blood clots/heart attacks? Who said that? The clinical trial doctors or the FDA? I firmly believe doctors know more about Iclusig than the FDA bureaucracy.
Ariad CEO did not expect the FDA would intentionally exaggerate the SAEs.
Before the plotted takedown happened, how could Harvey Berger know in advance the untrue accusation that falsely states "1 in 4 were getting blood clots / heart attacks"?
ARIA will become the next BIIB or AMGN although it is not comparable to the 2 companies right now.
The CEO's goal is to build Ariad into the next Amgen. I like Harvey Berger's goal and trust the Ariad CEO. It does not matter who told me about the goal. I like his goal and trust him.
You don't need to agree with me. And you don't need to trust HB.
an educated analyst from a fortune 500 company? Clearly the PPS is the final judge.
Quote:
I believe Rachel McMinn has again lost course. She was way late in coverage of Ariad a few years ago. Then, last September I believe, she raises Ariad from $25 to $30, including a value of $3 to $4 for AP26113. Recently, she has increased her price target from $2 to $3, giving Zero value for '113. She is absolutely clueless, imo, and is condescending on the CC with Ariad
Did Citi, BofA and Credit Sussie see Iclusig would return to the market within 2 months after it was withdrawn?
Credit Sussie did see the FDA came down hard on Ariad, though.
4. The poison pill provision on Nov. 1 was the most positive indication. It indicates that the next BIIB/AMGN is not for sale in addition to thwarting off hostile takeovers. It indicates that Ariad CEO is not knocked down by the unexpected setback or conspired takedown. The company remains confident on itself. It was the CEO's ego or his confidence on Ariad that help ariadinvestor and me decide to invest in the stock of this company 14 years ago.
3. Doctors and patients support Ariad as evidenced by the York Time article published on Nov. 1 and the Boston Globe article published on Nov. 24. The FDA has to listen to doctors and patients eventually. Otherwise, the FDA would face lawsuits by patients, investors and Ariad's legal team. Patients has planned legal filings as evidenced by the conversation between Hans Loland and Ariadinvestor on the Ariad Yahoo Message Board. If the patients had been forced to take legal actions in order to bring back Iclusig that is their lifeline, Ariad's legal actions would have followed the patients' actions, I believe.
2. The ASH Annual Meeting abstracts (published on Nov. 7) and Ariad Corporate Conference Calls (dated Oct. 9, Oct. 18 and Oct. 31, 2013) indicate that the FDA has intentionally exaggerated the lifesaving drug Iclusig's SAEs in order for it to come down hard on the company as observed by Crédit Suisse analyst Jason Kantor. I firmly believe doctors know more about Iclusig than the FDA bureaucracy.
1. FMR continues to buy and hold ARIA after the big plunge, which indicates the largest mutual fund is very confident on Ariad. Fidelity added 7.8 million shares, totally holding 27.4 million shares; Sarissa Capital bought 11.5 million shares; Camber Capital 10 million shares.
0. On Nov. 8, 2013, the EMA's PRAC recommended that Iclusig should continue to be used. I did not mention this in my previous post because it was too obvious to be mentioned.
4. The poison pill provision on Nov. 1 was the most positive indication. It indicates that the next BIIB/AMGN is not for sale in addition to thwarting off hostile takeovers. It indicates that Ariad CEO is not knocked down by the unexpected setback or conspired takedown. The company remains confident on itself. It was the CEO's ego or his confidence on Ariad that help ariadinvestor and me decide to invest in the stock of this company 14 years ago.
3. Doctors and patients support Ariad as evidenced by the York Time article published on Nov. 1 and the Boston Globe article published on Nov. 24. The FDA has to listen to doctors and patients eventually. Otherwise, the FDA would face lawsuits by patients, investors and Ariad's legal team. Patients has planned legal filings as evidenced by the conversation between Hans Loland and Ariadinvestor on the Ariad Yahoo Message Board. If the patients had been forced to take legal actions in order to bring back Iclusig that is their lifeline, Ariad's legal actions would have followed the patients' actions, I believe.
2. The ASH Annual Meeting abstracts (published on Nov. 7) and Ariad Corporate Conference Calls (dated Oct. 9, Oct. 18 and Oct. 31, 2013) indicate that the FDA has intentionally exaggerated the lifesaving drug Iclusig's SAEs in order for it to come down hard on the company as observed by Crédit Suisse analyst Jason Kantor. I firmly believe doctors know more about Iclusig than the FDA bureaucracy.
1. FMR continues to buy and hold ARIA after the big plunge, which indicates the largest mutual fund is very confident on Ariad. Fidelity added 7.8 million shares, totally holding 27.4 million shares; Sarissa Capital bought 11.5 million shares; Camber Capital 10 million shares.
0. On Nov. 8, 2013, the EMA's PRAC recommended that Iclusig should continue to be used. I did not mention this in my previous post because it was too obvious to be mentioned.
•Implementation of "poison pill" provision lessens a potential take-out scenario.
If you say that Fidelity added all the 7.8m shares during the period between Oct. 1 and Oct. 8 and therefore FMR did not continue to buy and hold ARIA at all after the crash, I won't ask you to provide the exact transaction dates although you do know them exactly. Nevertheless, I believe:
1. FMR increased by 7.8m to 27.4m shares per its 13G filed on Nov. 8, 2013 from 19.6m shares held by it on Sept. 30, 2013.
2. Fidelity's keeping buying and holding ARIA after the conspired takedown indicates the largest mutual fund company really knows what it owns.
No i asked because the information is relevant and I wanted to know.
It's not a fact that they added until you can demonstrate that their ownership has increased subsequent to the price decline. Which you have yet to do. Merely stating an ownership reported as of nov 8 without explaining what date they owned the stock as of is meaningless. Also you need to compare that ownership amount showing it was after the decline to a period before the decline to demonstrate that an increase occurred after. You have done none of this.
By the way the as of date means everything the reported date means nothing
If you are not capable of finding the date on the report yourself feel free to post a link and I can do it for you.
Why don't you find out FMR's purchase dates now that FMR has disclosed them to you in their report?
It's not impossible for you to prove grandma_of_jbraika was wrong in saying Fidelity added 7.8 million shares after the plotted takedown if all the 7.8m shares were added during the period between Oct. 1 and Oct. 8. I think you can.
You said
It's not impossible they disclose it in their report.
I don't think you need to piss off the FDA with a lawsuit when ARIA has many other drugs in the pipeline. IMO you move forward and accept it as a setback.
grandma, Berger suing the FDA will not yield anything positive and he knows that. It will only delay or decrease ARIAD's chance of recovering from the this Oct'13 mess. I agree with you that the FDA screwed up in their action big time but it also put ARIADs drug in the microscope for all the world to see and now that it has gone back to the limelight stronger than before, Ariad now has the leverage to put this drug in other indications much faster than before because the FDA will be a little hesitant to do something foolish again since it is the same drug, the same formula with probably just lesser dosage & lesser SAEs. ARIAD SUING the FDA, HB will be distracted from what he's doing best which is manage the business and science of ARIAD...just my 2 cents
I believe Rachel McMinn has again lost course. She was way late in coverage of Ariad a few years ago. Then, last September I believe, she raises Ariad from $25 to $30, including a value of $3 to $4 for AP26113. Recently, she has increased her price target from $2 to $3, giving Zero value for '113. She is absolutely clueless, imo, and is condescending on the CC with Ariad.
... including a value of $3 to $4 for AP26113.
This appears to be more BS from Rachel McMinn. No ONE, that I've seen, has modeled frontline treatment in any way, shape, or form for Iclusig in the short or medium term at all.
"In addition, we think the bullish discussion in Street
upgrades around Iclusig having option value as a frontline therapy is very much misplaced, as the safety profile, FDA label, and REMS program do not support first line."
ARIA Price Target Raised to $7.50 from $2.50 at UBS AG (ARIA)
http://tickerreport.com/banking-finance/99811/ariad-pharmaceuticals-price-target-raised-to-7-50-at-ubs-ag-aria/
Certain analyst reports are just advertisements promoting buying or selling a stock.
They are employed and paid for release such intentional advertisements. They could actually know less than you about ARIA.
Do you remember BMO's $37 price target?
"Wall Street wrongly participated that Ariad would bankrupt in 10/1999. But Ariad CEO turned things around magically.
ARIA dropped to $0.50 in Oct. 1999. 4 moths later in Feb. 2000, ARIA was as high as $48.50." - posted by araidinvestor on Oct. 11, 2013
I have never listened to some of the so-called analysts such as BOA's, BMO's and Citi's. They are truly paid pumpers and bashers.
... potential downside from future updates.
Ariad develops lifesaving drugs for the cancer patients. In addition to Iclusig, Ariad has another lifesaving drug AP26113 for lung cancer patients. Ariad has a great lab that is working on still another molecule which will be announced this year as a best-in-class cancer drug targeting solid tumor.
Positive indications seen after the Oct.9 plotted takedown:
1. FMR continues to buy and hold ARIA after the big plunge, which indicates the largest mutual fund is very confident on Ariad. Fidelity added 7.8 million shares, totally holding 27.4 million shares; Sarissa Capital bought 11.5 million shares; Camber Capital 10 million shares.
2. The ASH Annual Meeting abstracts (published on Nov. 7) and Ariad Corporate Conference Calls (dated Oct. 9, Oct. 18 and Oct. 31, 2013) indicate that the FDA has intentionally exaggerated the lifesaving drug Iclusig's SAEs in order for it to come down hard on the company as observed by Crédit Suisse analyst Jason Kantor. I firmly believe doctors know more about Iclusig than the FDA bureaucracy.
3. Doctors and patients support Ariad as evidenced by the York Time article published on Nov. 1 and the Boston Globe article published on Nov. 24. The FDA has to listen to doctors and patients eventually. Otherwise, the FDA would face lawsuits by patients, investors and Ariad's legal team. Patients has planned legal filings as evidenced by the conversation between Hans Loland and Ariadinvestor on the Ariad Yahoo Message Board. If the patients had been forced to take legal actions in order to bring back Iclusig that is their lifeline, Ariad's legal actions would have followed the patients' actions, I believe.
4. The best indication is the poison pill adoption on Nov. 1 for thwarting off hostile takeovers. The poison pill indicates that Ariad CEO is not knocked down by the unexpected setback or conspired takedown. The company remains confident on itself.
Influenced & Encouraged by the positive indications we saw after the conspired flash crash, many of our friends bought/added thousands and thousands of ARIA shares at low prices between $2.xx and $4.xx.
Buy and hold the gold bags of ARIA shares. You won't regret if you are a long term investor. I agree with ariadinvestor.
ARIA will become the next BIIB or AMGN, at least it seems to me.
FMR increased by 7.8m to 27.4m shares per its 13G filed on Nov. 8, 2013 from 19.6m shares held by it on Sept. 30, 2013.
Fidelity's keeping buying and holding ARIA after the conspired crash indicates the largest mutual fund company really knows what it owns.
If somebody argues that Fidelity added all the 7.8m shares during the period between Oct. 1 and Oct. 8 and therefore FMR did not continue to buy and hold ARIA at all after the crash, I will not ask him to provide the exact transaction dates, for I do not know the exact purchase dates, either.